Mayo Clinic Laboratories > Neurology > Dementia

Dementia

Advancing understanding of a debilitating disease

Mayo Clinic Laboratories is a one-stop laboratory solution for dementia testing, offering the industry’s most sophisticated suite of testing available. Including biomarker evaluations, autoimmune panels, testing for rapidly progressive cases, and an innovative combination assay, our expert-developed menu drives precision answers that enhance patient care.

Because federally approved treatments are available for Alzheimer’s disease and some types of autoimmune dementia – including rapidly progressive cases that can potentially be reversed – accurate, expedient diagnosis can improve some patients’ outcomes. However, due to overlapping symptoms, distinguishing the correct diagnosis can be challenging, often requiring multiple laboratory tests and extended time to diagnosis. Our dementia testing streamlines diagnosis, providing faster answers to guide patient care.

Alzheimer’s disease Alzheimer’s disease
Alzheimer’s disease

Our Alzheimer's disease evaluations use cerebrospinal fluid biomarkers to achieve a high concordance with amyloid positron emission tomography (PET) scans and have been optimized to reduce pre-clinical variability, these clinically validated tests deliver fast, accurate answers that can improve access to Alzheimer’s disease treatments.

Autoimmune dementia Autoimmune dementia
Autoimmune dementia

Our autoimmune dementia panel uses a reflexive, algorithmic approach and multiple methodologies, including indirect immunofluorescence assay (IFA), cell-binding assay, immunoblot, radioimmunoassay, and Western blot to detect for nearly 20 neural antibodies associated with autoimmune dementia.

News and updates

The latest

FDA-approved test expands options for Alzheimer’s disease

Joshua Bornhorst, Ph.D., describes the new, FDA-approved Alzheimer's disease (AD) test and how it differs from Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to ensure flexibility and options for managing clinical care.

Learn more
The Role of CSF in Alzheimer’s Disease

This "Specialty Testing" webinar will discuss Cerebrospinal fluid (CSF), which has been used in research on Alzheimer's disease for decades. Only recently, have platforms been developed to standardize measurements across laboratories.

Alzheimer’s Disease Evaluation [A Test in Focus]

Currently the diagnosis of probable Alzheimer disease (AD) is made based on clinical symptoms, largely by the exclusion of other causes of dementia, with postmortem evidence of AD pathology required to confirm the diagnosis. Two common neuropathologic features found in the brains of patients with AD are the presence of plaques composed of beta-amyloid (Abeta) peptides and intracellular neurofibrillary tangles containing hyperphosphorylated Tau (tubulin-associated unit) proteins.

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.